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Pulmonary Disease,  




 Cor pulmonale or right ventricular (RV) enlargement is cardiovascular 
complications of the chronic obstructive pulmonary disease (COPD). Hypoxic pulmonary 
vasoconstriction, hypercapnia, acidosis and pulmonary vascular remodeling are suggested as 
possible mechanisms of cor pulmonale. In this study, we aimed to evaluate the correlation 
between acidosis and hypercapnia with corpulmonale in patients with COPD. 
 In this cross-sectional analytical study, 100 patients (56 men and 44 women with 
mean age of 66.53 ± 10.63 years) with moderate to severe COPD exacerbation were included. 
Complete history taking and physical examination as well as atrial blood gas, pulmonary 
function test (PFT) and echocardiography were performed. Disease severity was defined 
according to global initiative for obstructive lung disease (GOLD), Modified Medical Research 
Council (mMRC) and COPD Assessment Test (CAT) criteria. Patients with cor pulmonale were 
defined and findings were compared between patients with and without cor pulmonale. 
 Forty-two patients had cor pulmonale. There was no significant difference in 
hypercapnia between groups. Cor pulmonale patients, compared to non-cor pulmonale, had 
significantly lower forced expiratory volume in the first second (FEV1) (P = 0.020), higher 
tricuspid regurgitation (TR) (P = 0.001) and pulmonary hypertension (P = 0.020). There was 
significantly negative correlation between RV thickness with FEV1/forced vital capacity (FCV) 
(r = -0.239, P = 0.010) and RV size with FEV1/FVC (r = -0.312, P = 0.002) and positive 
correlation with partial pressure of carbon dioxide (PaCO2) (r = 0.312, P = 0.002) and 
bicarbonate (HCO3) (r = 0.258, P = 0.009). 
 Cor pulmonale in the course of COPD accompanies with adverse outcome. These 
patients have worth spirometry and left ventricle echocardiographic findings, but have no 
difference in arterial blood gas (ABG) findings. 
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Cor pulmonale describes the enlargement 
and failure of the right ventricle of the heart 
as a response to increased vascular resistance 
or increased pulmonary artery pressure.1-3 It 
is a common complication of chronic 
obstructive pulmonary disease (COPD) with 
incidence rate of 20-30%.1-4 
COPD is considered as one of the main 
causes of morbidity and mortality worldwide 
and is characterized by progressive airway 
obstruction leading to reduced lung function 
and breathlessness.3,5 Hypoxic pulmonary 
vasoconstriction, hypercapnia, respiratory 
acidosis and pulmonary vascular remodeling 
in COPD can cause an increase in right 
ventricular (RV) afterload, which in turn, 
results in RV failure leading to cor 
pulmonale.6,7 The severity of cor pulmonale 
in COPD patients is dependent to hypoxia, 
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hypercapnia and airway obstruction as it has 
been reported a prevalence of 40% in patients 
with forced expiratory volume in the first 
second (FEV1) < 1 l and 70% in patients with 
FEV1 < 0.6 l.  
With controlling and treatment of the 
causes and risk factors of cor pulmonale, it is 
possible to prevent the disease progress and 
reduce the morbidity and mortality rate.8 
Due to presumed role of acidosis and 
hypercapnia for cor pulmonale in COPD 
patients, in this study we aimed to evaluate 
the correlation between acidosis and 
hypercapnia with corpulmonale in patients 
with COPD. 
 
In this cross-sectional study, 100 patients 
with COPD exacerbation, global initiative for 
obstructive lung disease (GOLD) stage II-IV, 
FEV1 predicted < 60% and chronic hypoxia 
[partial pressure of oxygen (PaO2) < 60 
mmHg)] admitted to Imam Khomeini 
Hospital, Ardabil, Iran, between February 
2016 and February 2017 were included. 
Patients with previous or current pulmonary 
thromboemboli, obstructive sleep apnea, 
interstitial lung disease, left heart disease or 
left ventricular dysfunction due to ischemic 
heart disease, cardiomyopathies, congenital 
heart diseases, valvular heart disease, or 
other cardiovascular disease, malignancy, 
metabolic conditions, malnutrition, muscular 
disease, systemic inflammatory diseases, or 
renal failure, collagen vascular disease and 
idiopathic pulmonary hypertension were 
excluded. The study protocol was reviewed 
and approved by the Ethics Committee of 
Ardabil University of Medical Sciences. All 
patients were provided with written 
informed consent prior to enrolment. 
Study protocol: Detailed clinical history 
and physical examination were obtained in 
each patient. Demographic, laboratory, 
electrocardiogram (ECG), chest X-ray 
findings were recorded. Atrial blood gas 
(ABG) was taken to evaluate the respiratory 
acidosis and hypercapnia. ABG was 
determined at patients' arrival to the 
emergency department with a FiO2 of 21%. 
All patients underwent echocardiography. 
The severity of COPD was staged according 
to the GOLD guidelines.9 The modified 
Medical Research Council (mMRC)10 scale 
and the COPD Assessment Test (CAT) were 
also recorded. CAT is an eight-item 
questionnaire designed to quantify the 
impact of COPD symptoms on the health 
status of patients, with higher values 
indicative of worse health status.11 
The patients were put into two subgroups, 
COPD with and without cor pulmonale. Cor 
pulmonale was diagnosed based on an 
established clinical history of cor pulmonale or 
the current clinical evidence, chest 
radiography, ECG, and echocardiography. 
Findings regarding RV hypertrophy or dilation 
and RV dysfunction in echocardiography were 
required for the enrollment.  
All patients underwent spirometry and 
FEV1, forced vital capacity (FVC) and 
FEV1/FVC ratio were recorded.  
A cardiovascular ultrasound system 
(Vivid E9, General Electric, Horten, Norway) 
was used to perform echocardiography, 
using M mode and two-dimensional 
ultrasonography. RV thickness and size, right 
ventricular hypertrophy (RVH), tricuspid 
regurgitation (TR) were recorded. 
Continuous wave Doppler was used to detect 
TR and calculate the systolic pulmonary 
artery pressure (sPAP). Pulmonary artery 
hypertension (PAH) was considered if sPAP 
value was above 30 mmHg and divided into 
mild (30-50 mmHg), moderate (50-70 mmHg) 
and severe (< 70 mmHg).12  
All data were analyzed using SPSS software 
(version 17, SPSS Inc., Chicago, IL, USA). 
Results are expressed as mean ± standard 
deviation (SD) or percentage. To compare the 
parameters, Student's independent t-test, 
analysis of variance (ANOVA) and chi-square 
or Fisher’s exact tests were used to compare 
data between groups of patients. Pearson 
correlation was used to define possible 
correlations between echocardiographic and 
ABG and Pulmonary function test (PFT) 
findings, as well as between CAT and MMRC 
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scores. P of less than 0.050 was considered 
statistically significant. 
 
One-hundred patients including 56 men and 
44 women with mean age of 66.53 ± 10.63 
were studied. Mean duration of the disease 
was 12.50 ± 5.44 years. Comorbidities were 
diabetes mellitus (3 cases), hypertension  
(51 cases) and smoking (93 cases). Eighty-five 
patients had hypercapnia and 86 had 
respiratory acidosis. Cor pulmonale was 
present in 42 patients based on 
echocardiography findings.   
Mean CAT score was 15.44 ± 10.84 and 
mean MMRC was 3.00 ± 0.81. According to 
GOLD criteria, 23 had stage II, 52 had stage 
III and 25 had stage IV. There was 
significantly positive correlation between 
CAT score and MMRC (r = 0.673, P < 0.001). 
Mean CAT score in GOLD stage II, III and IV 
were 7.26 ± 1.76, 13.59 ± 1.18 and 26.80 ± 7.69, 
respectively. With the increase in the GOLD 
stage, CAT score and health status were 
worsened (P < 0.001). 
Demographic and clinical findings 
among COPD patients with and without 
cor pulmonale are shown in table 1. We 
found no significant difference among these 
variables between groups. Although cor 
pulmonale patients had higher CAT score 
and MMRC and more cases with a  
higher stage of GOLD, the difference was  
not significant. 
Table 2 demonstrates PFT, ABG and 
echocardiography findings between COPD 
patients with and without cor pulmonale. 
Cor pulmonale patients had significantly 
lower FEV1, higher TR and pulmonary 
hypertension. PFT, ABG and 
echocardiography variables were similar 
between groups. Hypercapnia prevalence 
was similar between groups. Also, 36 (42.4%) 
of patients with hypercapnia and 6 (40.0%) of 
patients with normocapnia had cor 
pulmonale (P = 0.900).  
We found significant correlations between 
RV thickness with FEV1/FVC (r = -0.239,  
P = 0.010) and RV size with FEV1/FVC  
(r = -0.312, P = 0.002) and between RV size 
and partial pressure of carbon dioxide 
(PaCO2) (r = 0.312, P = 0.002) and bicarbonate 
(HCO3) (r = 0.258, P = 0.009). 
 
In our study, 100 patients with COPD 
including 56 men with mean age of  
66.53 years were studied. We found cor 
pulmonale in 42 cases. In previous studies, 
COPD has been more prevalent in men, older 
age, lower socioeconomic state and 
smokers.13  
 
Table 1. Demographic and clinical findings between chronic obstructive pulmonary disease (COPD) patients with and 
without cor pulmonale 
Variable With cor pulmonale Without cor pulmonale P
*
 
Age (year) (mean ± SD) 65.85 ± 9.97 67.01 ± 11.14 0.590 
Sex [n (%)] Male 28 (66.7) 28 (48.3) 0.100 
Female 14 (33.3) 30 (51.7) 
BMI (kg/m
2
) (mean ± SD) 27.98 ± 6.08 27.02 ± 4.71 0.370 
Disease duration (year) (mean ± SD) 13.25 ± 5.93 11.96 ± 5.05 0.250 
Diabetes mellitus [n (%)] 1 (2.4) 2 (3.4) 0.750 
Hypertension [n (%)] 19 (45.2) 32 (55.2) 0.320 
Chronic cough [n (%)] 38 (90.5) 57 (98.3) 0.070 
Chronic sputum [n (%)] 41 (97.6) 58 (100) 0.420 
Edema [n (%)] 31 (37.8) 34 (58.6) 0.110 
CAT score (mean ± SD) 17.85 ± 10.73 13.68 ± 10.66 0.057 
MMRC score (mean ± SD) 3.00 ± 0.79 2.75 ± 0.82 0.140 
GOLD stage [n (%)] II 6 (14.3) 17 (29.3) 0.056 
III 21 (50.0) 31 (53.4) 
IV 15 (35.7) 10 (17.2) 
*Student's independent t-test, analysis of variance (ANOVA), chi-square or Fisher’s exact tests  
SD: Standard deviation; BMI: Body mass index; CAT: COPD Assessment Test; mMRC: Modified Medical Research Council; 
GOLD: Global initiative for obstructive lung disease 
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Table 2. Pulmonary function test (PFT), arterial blood gas (ABG) and echocardiographic findings between chronic 
obstructive pulmonary disease (COPD) patients with and without cor pulmonale 
Variable With cor pulmonale Without cor pulmonale P
*
 
PFT (mean ± SD)    
O2Sat 76.69 ± 7.65 80.51 ± 6.03 0.540 
FEV1 34.30 ± 13.77 40.77 ± 14.76 0.020
*
 
FVC 47.40 ± 16.85 52.68 ± 16.71 0.120 
FEV1/FVC 0.61 ± 0.06 0.64 ± 0.05 0.070 
ABG (mean ± SD)    
pH 7.28 ± 0.07 7.30 ± 0.06 0.200 
PaO2 53.07 ± 5.25 53.94 ± 6.11 0.450 
PaCO2 60.32 ± 13.20 56.36 ± 12.31 0.120 
HCO3 29.90 ± 5.29 28.04 ± 4.44 0.060 
Hypercapnia [n (%)] 36 (85.7) 49 (84.5) 0.860 
Echocardiography (mean ± SD)    
RV size 3.60 ± 1.06 3.13 ± 1.41 0.060 
TR [n (%)] 28 (66.7) 19 (32.8) 0.001
*
 




Mild 6 (14.3) 9 (15.5) 
Moderate 8 (19.0) 7 (12.1) 
Severe 11 (26.2) 4 (6.9) 
*Student's independent t-test, analysis of variance (ANOVA), chi-square or Fisher’s exact tests 
SD: Standard deviation; PFT: Pulmonary function test; O2Sat: Oxygen saturated; FEV1: forced expiratory volume in the first 
second; FVC: Forced vital capacity; ABG: Arterial blood gas; PaO2: Partial pressure of oxygen; PaCO2: Partial pressure of carbon 
dioxide; HCO3: Bicarbonate; RV: Right ventricular; TR: Tricuspid regurgitation 
 
In COPD patients, hypoxemia, 
hypercapnia, inflammation and vascular 
changes due to airway dilatation and changes 
in RV pressure lead to RV dysfunction and 
right heart failure.14 Cor pulmonale is the 
main cardiac side effect of COPD15 and is 
considered as the main cause of mortality 
and morbidity in COPD.16 
We observed cor pulmonale in 42.0% of 
COPD patients. Similarly, Gupta et al.17 
reported cor pulmonale in 41.2%. The 
prevalence was 48.1% in the study of  
Ju et al.18   
In our study, cor pulmonale patients were 
mostly men with longer duration of the 
disease and higher body mass index (BMI). 
Similarly, in the study of Ju et al,18 patients 
with and without cor pulmonale had similar 
age and sex with higher prevalence in men, 
lower BMI and lower O2 saturation with no 
difference between groups. 
Cor pulmonale patients in our study had 
lower FVC and FEV1/FVC, but there was the 
only significant difference between groups in 
the lower FEV1. ABG findings were not 
different between groups. There was no 
difference between hypercapnic and 
normocapnic COPD patients in the 
prevalence of COPD. Ju et al.18 observed that 
cor pulmonale patients had lower FEV1 and 
FEV1/FVC. Unlike our findings, Yang et al.19 
observed that cor pulmonale was 
significantly higher in hypercapnic as 
compared to normocapnic patients. Verbitskii 
et al.20 reported insignificant hypoxemia in 
cor pulmonale, which progressed with 
decompensation of chronic cor pulmonale. 
In our study, cor pulmonale patients had 
significantly higher TR and pulmonary 
hypertension with a higher incidence of 
moderate and severe types. Likewise, Ju et 
al.18 reported higher sPAP and RV thickness 
in cor pulmonale patients. Gupta et al.17 
observed that in corpulmonale patients, 
pulmonary hypertension prevalence is higher 
and with an increase in the severity of PHTN, 
the cases with cor pulmonale increases.  
We also found significant negative 
correlations between FEV1/FVC with size 
and thickness of RV and positive correlation 
between RV size with PaCO2 and HCO3. We 
found a significantly positive correlation 
between CAT score and MMRC in COPD 
patients. We also observed that with an 
increase in the GOLD stage, CAT score and 
health status were worsened. 
Cor pulmonale and COPD 
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In our study, cor pulmonale patients had 
higher CAT score and MMRC and more cases 
with a higher stage of GOLD, but the 
difference was not significant. Ju et al.18 
showed that stage IV GOLD was significantly 
higher in cor pulmonale patients. 
 
In conclusion, Cor pulmonale, in the course 
of COPD, accompanies with adverse 
outcome. These patients have worth 
spirometry and left ventricle 
echocardiographic findings, but have no 
difference in ABG findings. 
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